AlphAIalphai — Financial news for AI agents
StockNYSE · US · USDHealthcare · Drug Manufacturers - Specialty & Generic

$TAK

TAKEDA PHARMACEUTICAL CO LTD

Insider trades
Price · $TAKvia TradingView
AI sentiment · 7d4 articles
AUG 12net (bullish − bearish)AUG 18
Bullish
2
Neutral
2
Bearish
0
Insider · 30dAll trades →
Buys
—
0 txs
Sells
$9.7M
16 txs
Greenway Nicola Deidre Petal3× · $722K
10b5-1 share of filings0%
See all $TAK insider activity →
Top stories · $TAKMore →
AUG 18·smithsonianmag.comMed

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

AUG 15·en.majalla.com

The brain may be about to have its Ozempic moment

The article discusses orexin receptor drugs for sleep disorders. Orexin antagonists already treat insomnia by reducing wakefulness. It focuses on orexin agonists, including Takeda’s oveporexton, which in an 8-week trial of 90 patients extended wakefulness by 12.5 to 25 minutes versus placebo and reduced cataplexy frequency by about one third, with insomnia and urinary urgency as side effects. It also notes Lilly’s orexin agonist in trials for NT1 and NT2.

TAK sentiment & insider activity

Over the past 7 days, alphai's AI scored 4 news stories mentioning TAK (TAKEDA PHARMACEUTICAL CO LTD). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.

Recent TAK coverage spans insider activity, regulation and technology.

In the last 30 days, TAK insiders filed 16 SEC Form 4 transactions — no purchases and 16 sales ($9.7M). The most active reporter was Greenway Nicola Deidre Petal, Chief Human Resources Officer, with 3 filings.

What's driving TAK

  • Regulatory approval of a root-cause orexin-mimicking therapy can re-rate Takeda’s sleep-disorder pipeline and support near-term sentiment.

    smithsonianmag.com · Aug 18, 2026

  • FDA approval is a fundamental positive catalyst for ORZEYFUL commercialization prospects, but the article provides no new commercial metrics beyond the approval fact.

    simplywall.st · Aug 18, 2026

  • Clinical efficacy and tolerability details for Takeda’s orexin agonist could shift expectations for NT1/NT2 development, but the piece is still early-stage and not a regulatory decision.

    en.majalla.com · Aug 15, 2026

  • For Takeda, the event is a small cash outflow within a large commercial base, with limited direct earnings impact but signaling ongoing development momentum.

    yahoo.com · Aug 15, 2026

  • This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.

    SEC EDGAR · Aug 13, 2026

alphai scores every news story that mentions TAK with an AI model for sentiment and relevance, and aggregates insider trades from TAKEDA PHARMACEUTICAL CO LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TAK

Score
AUG 18$TAKMedAI 8/10smithsonianmag.com

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

4 min read
AUG 15$TAKLowen.majalla.com

The brain may be about to have its Ozempic moment

The article discusses orexin receptor drugs for sleep disorders. Orexin antagonists already treat insomnia by reducing wakefulness. It focuses on orexin agonists, including Takeda’s oveporexton, which in an 8-week trial of 90 patients extended wakefulness by 12.5 to 25 minutes versus placebo and reduced cataplexy frequency by about one third, with insomnia and urinary urgency as side effects. It also notes Lilly’s orexin agonist in trials for NT1 and NT2.

7 min read
AUG 15$KROSMedyahoo.com

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

Keros Therapeutics (NASDAQ:KROS) said it received a $20 million development milestone from Takeda (NYSE:TAK) after the first patient was dosed in Phase 3 ELRiSE MDS. The trial compares elritercept with epoetin alfa for anemia in low-to-intermediate-risk MDS. Keros previously got a $200 million upfront payment and may earn over $1.1 billion more milestones plus royalties, and plans to distribute 25% of the $20 million net proceeds to shareholders.

6 min read

Related tickers

More in Drug Manufacturers - Specialty & Generic